Bortezomib in mantle cell lymphoma

Comparative therapeutic outcomes

Nishanth Vallumsetla, Jonas Paludo, Prashant Kapoor

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Mantle cell lymphoma (MCL) is an incurable, typically aggressive subtype of non-Hodgkin lymphoma, accounting for 4%–7% of newly diagnosed non-Hodgkin lymphoma cases. Chemoresistance commonly ensues in MCL, and patients with this heterogeneous disease invariably relapse, underscoring the unmet need for better therapies. Over the past few years, several novel agents with promising activity and unique mechanisms of action have been deemed effective in MCL. Bortezomib is a reversible proteasome inhibitor, approved as a single agent for patients with relapsed/refractory MCL who have received at least one prior line of therapy. Addition of bortezomib to chemoimmunotherapies has demonstrated good tolerability and superior efficacy, both in the upfront and salvage settings, and recently one such combination of bortezomib plus rituximab, cyclophosphamide, doxorubicin, and prednisone was approved as a frontline regimen in untreated patients with MCL. This review examines the role of bortezomib in a multitude of clinical settings and ongoing clinical trials designed to optimize its integration in the current treatment paradigms of MCL.

Original languageEnglish (US)
Pages (from-to)1663-1674
Number of pages12
JournalTherapeutics and Clinical Risk Management
Volume11
DOIs
StatePublished - Nov 6 2015

Fingerprint

Mantle-Cell Lymphoma
Salvaging
relapse
Refractory materials
paradigm
Disease
Non-Hodgkin's Lymphoma
Proteasome Inhibitors
Therapeutics
Prednisone
Doxorubicin
Cyclophosphamide
Proxy
Bortezomib
Clinical Trials
Recurrence
Proteasome Endopeptidase Complex

Keywords

  • Non-Hodgkin lymphoma
  • Proteosome inhibitor
  • Treatment

ASJC Scopus subject areas

  • Medicine(all)
  • Safety Research
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Chemical Health and Safety
  • Pharmacology (medical)

Cite this

Bortezomib in mantle cell lymphoma : Comparative therapeutic outcomes. / Vallumsetla, Nishanth; Paludo, Jonas; Kapoor, Prashant.

In: Therapeutics and Clinical Risk Management, Vol. 11, 06.11.2015, p. 1663-1674.

Research output: Contribution to journalReview article

@article{b187fdcde061402288675b945e44a2e9,
title = "Bortezomib in mantle cell lymphoma: Comparative therapeutic outcomes",
abstract = "Mantle cell lymphoma (MCL) is an incurable, typically aggressive subtype of non-Hodgkin lymphoma, accounting for 4{\%}–7{\%} of newly diagnosed non-Hodgkin lymphoma cases. Chemoresistance commonly ensues in MCL, and patients with this heterogeneous disease invariably relapse, underscoring the unmet need for better therapies. Over the past few years, several novel agents with promising activity and unique mechanisms of action have been deemed effective in MCL. Bortezomib is a reversible proteasome inhibitor, approved as a single agent for patients with relapsed/refractory MCL who have received at least one prior line of therapy. Addition of bortezomib to chemoimmunotherapies has demonstrated good tolerability and superior efficacy, both in the upfront and salvage settings, and recently one such combination of bortezomib plus rituximab, cyclophosphamide, doxorubicin, and prednisone was approved as a frontline regimen in untreated patients with MCL. This review examines the role of bortezomib in a multitude of clinical settings and ongoing clinical trials designed to optimize its integration in the current treatment paradigms of MCL.",
keywords = "Non-Hodgkin lymphoma, Proteosome inhibitor, Treatment",
author = "Nishanth Vallumsetla and Jonas Paludo and Prashant Kapoor",
year = "2015",
month = "11",
day = "6",
doi = "10.2147/TCRM.S72943",
language = "English (US)",
volume = "11",
pages = "1663--1674",
journal = "Therapeutics and Clinical Risk Management",
issn = "1176-6336",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Bortezomib in mantle cell lymphoma

T2 - Comparative therapeutic outcomes

AU - Vallumsetla, Nishanth

AU - Paludo, Jonas

AU - Kapoor, Prashant

PY - 2015/11/6

Y1 - 2015/11/6

N2 - Mantle cell lymphoma (MCL) is an incurable, typically aggressive subtype of non-Hodgkin lymphoma, accounting for 4%–7% of newly diagnosed non-Hodgkin lymphoma cases. Chemoresistance commonly ensues in MCL, and patients with this heterogeneous disease invariably relapse, underscoring the unmet need for better therapies. Over the past few years, several novel agents with promising activity and unique mechanisms of action have been deemed effective in MCL. Bortezomib is a reversible proteasome inhibitor, approved as a single agent for patients with relapsed/refractory MCL who have received at least one prior line of therapy. Addition of bortezomib to chemoimmunotherapies has demonstrated good tolerability and superior efficacy, both in the upfront and salvage settings, and recently one such combination of bortezomib plus rituximab, cyclophosphamide, doxorubicin, and prednisone was approved as a frontline regimen in untreated patients with MCL. This review examines the role of bortezomib in a multitude of clinical settings and ongoing clinical trials designed to optimize its integration in the current treatment paradigms of MCL.

AB - Mantle cell lymphoma (MCL) is an incurable, typically aggressive subtype of non-Hodgkin lymphoma, accounting for 4%–7% of newly diagnosed non-Hodgkin lymphoma cases. Chemoresistance commonly ensues in MCL, and patients with this heterogeneous disease invariably relapse, underscoring the unmet need for better therapies. Over the past few years, several novel agents with promising activity and unique mechanisms of action have been deemed effective in MCL. Bortezomib is a reversible proteasome inhibitor, approved as a single agent for patients with relapsed/refractory MCL who have received at least one prior line of therapy. Addition of bortezomib to chemoimmunotherapies has demonstrated good tolerability and superior efficacy, both in the upfront and salvage settings, and recently one such combination of bortezomib plus rituximab, cyclophosphamide, doxorubicin, and prednisone was approved as a frontline regimen in untreated patients with MCL. This review examines the role of bortezomib in a multitude of clinical settings and ongoing clinical trials designed to optimize its integration in the current treatment paradigms of MCL.

KW - Non-Hodgkin lymphoma

KW - Proteosome inhibitor

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84946842810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946842810&partnerID=8YFLogxK

U2 - 10.2147/TCRM.S72943

DO - 10.2147/TCRM.S72943

M3 - Review article

VL - 11

SP - 1663

EP - 1674

JO - Therapeutics and Clinical Risk Management

JF - Therapeutics and Clinical Risk Management

SN - 1176-6336

ER -